Switch theme
Sign up to access all valuation multiples
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
2013
8.4K+
LTM Revenue $4.4B
LTM EBITDA $751M
$6.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Perrigo has a last 12-month revenue (LTM) of $4.4B and a last 12-month EBITDA of $751M.
In the most recent fiscal year, Perrigo achieved revenue of $4.4B and an EBITDA of $433M.
Perrigo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Perrigo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | XXX | $4.4B | XXX | XXX | XXX |
| Gross Profit | $1.7B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Margin | 39% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $751M | XXX | $433M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $638M | XXX | $312M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $382M | XXX | -$172M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | -4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Perrigo's stock price is $27.
Perrigo has current market cap of $3.7B, and EV of $6.9B.
See Perrigo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.9B | $3.7B | XXX | XXX | XXX | XXX | $2.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Perrigo has market cap of $3.7B and EV of $6.9B.
Perrigo's trades at 1.6x EV/Revenue multiple, and 15.9x EV/EBITDA.
Equity research analysts estimate Perrigo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Perrigo has a P/E ratio of 9.6x.
See valuation multiples for Perrigo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $6.9B | XXX | $6.9B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | 15.9x | XXX | XXX | XXX |
| EV/EBIT | 10.8x | XXX | 22.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.6x | XXX | -21.4x | XXX | XXX | XXX |
| EV/FCF | 16.1x | XXX | 28.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPerrigo's last 12 month revenue growth is 2%
Perrigo's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Perrigo's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Perrigo's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Perrigo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Perrigo acquired XXX companies to date.
Last acquisition by Perrigo was XXXXXXXX, XXXXX XXXXX XXXXXX . Perrigo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Perrigo founded? | Perrigo was founded in 2013. |
| Where is Perrigo headquartered? | Perrigo is headquartered in United States of America. |
| How many employees does Perrigo have? | As of today, Perrigo has 8.4K+ employees. |
| Who is the CEO of Perrigo? | Perrigo's CEO is Mr. Patrick Lockwood Taylor. |
| Is Perrigo publicy listed? | Yes, Perrigo is a public company listed on NYS. |
| What is the stock symbol of Perrigo? | Perrigo trades under PRGO ticker. |
| When did Perrigo go public? | Perrigo went public in 1991. |
| Who are competitors of Perrigo? | Similar companies to Perrigo include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Perrigo? | Perrigo's current market cap is $3.7B |
| What is the current revenue of Perrigo? | Perrigo's last 12 months revenue is $4.4B. |
| What is the current revenue growth of Perrigo? | Perrigo revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Perrigo? | Current revenue multiple of Perrigo is 1.6x. |
| Is Perrigo profitable? | Yes, Perrigo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Perrigo? | Perrigo's last 12 months EBITDA is $751M. |
| What is Perrigo's EBITDA margin? | Perrigo's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Perrigo? | Current EBITDA multiple of Perrigo is 9.2x. |
| What is the current FCF of Perrigo? | Perrigo's last 12 months FCF is $429M. |
| What is Perrigo's FCF margin? | Perrigo's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Perrigo? | Current FCF multiple of Perrigo is 16.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
